Corvus Pharmaceuticals, Inc. (CRVS)

Market Cap	515.42M
Revenue (ttm)	n/a
Net Income (ttm)	-56.83M
Shares Out	62.55M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	518,308
Open	8.34
Previous Close	8.40
Day's Range	8.02 - 8.39
52-Week Range	1.30 - 10.00
Beta	1.04
Analysts	Buy
Price Target	12.83 (+55.7%)
Earnings Date	Nov 12, 2024

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also develop...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 23, 2016
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: CRVS
• Website: https://www.corvuspharma.com

Analyst Forecast

According to 4 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $12.83, which is an increase of 55.70% from the latest price.

Price Target

$12.83

(55.70% upside)

Analyst Consensus: Buy